Analyst Ratings For Mirati Therapeutics (NASDAQ:MRTX)
Today, HC Wainwright raised its price target on Mirati Therapeutics (NASDAQ:MRTX) to per share.
Some recent analyst ratings include
- 3/12/2018-Barclays initiated coverage with a Overweight rating.
- 1/8/2018-Cann Reiterated Rating of Buy.
- 12/21/2017-Cowen initiated coverage with a Outperform rating.
Recent Insider Trading Activity For Mirati Therapeutics (NASDAQ:MRTX)
Mirati Therapeutics (NASDAQ:MRTX) has insider ownership of 5.10% and institutional ownership of 82.89%.
- On 3/1/2018 Jamie A Donadio, CFO, sold 51,875 with an average share price of $27.13 per share and the total transaction amounting to $1,407,368.75.
- On 2/6/2018 Jamie Christensen, SVP, sold 23,000 with an average share price of $30.00 per share and the total transaction amounting to $690,000.00.
- On 1/26/2018 Jamie Christensen, SVP, sold 12,500 with an average share price of $26.11 per share and the total transaction amounting to $326,375.00.
- On 1/16/2018 Jamie Christensen, SVP, sold 10,814 with an average share price of $27.00 per share and the total transaction amounting to $291,978.00.
- On 1/11/2018 Jamie Christensen, SVP, sold 14,725 with an average share price of $22.99 per share and the total transaction amounting to $338,527.75.
- On 11/16/2017 Jamie Christensen, SVP, sold 10,275 with an average share price of $18.00 per share and the total transaction amounting to $184,950.00.
- On 11/16/2017 Venbio Select Advisor Llc, Major Shareholder, bought 650,000 with an average share price of $13.00 per share and the total transaction amounting to $8,450,000.00.
Recent Trading Activity for Mirati Therapeutics (NASDAQ:MRTX)
Shares of Mirati Therapeutics closed the previous trading session at 37.30 up +2.70 7.80% with 35.04999923706055 shares trading hands.